Case Fatality Rate and Severity of COVID-19 among Patients with Sickle Cell Disease: A Systematic Review and Meta-Analysis

References

• World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2020.
   Google Scholar
• Andersen KG, Rambaut A, Lipkin WI, et al. The proximal origin of SARS-CoV-2. Nat Med. 2020;26(4):450–452.
   PubMed Web of Science ®Google Scholar
• Zhu N, Zhang D, Wang W, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727–733.
   PubMed Web of Science ®Google Scholar
• Borges do Nascimento IJ, O’Mathúna DP, von Groote TC, et al. Coronavirus disease (COVID-19) pandemic: an overview of systematic reviews. BMC Infect Dis. 2021;21(1):24.
   PubMed Web of Science ®Google Scholar
• Worldometers. COVID-19 CORONAVIRUS PANDEMIC. https://www.worldometers.info/coronavirus/. 2021.
   Google Scholar
• Gandhi RT, Lynch JB, del Rio C. Mild or moderate Covid-19. N Engl J Med. 2020;383(18):1757–1766.
   PubMed Web of Science ®Google Scholar
• Wu C, Chen X, Cai Y, et al. Risk factors associated with acute respiratory distress syndrome and death in patients with Coronavirus disease 2019 pneumonia in Wuhan, China. JAMA Intern Med. 2020;180(7):934–943.
   PubMed Web of Science ®Google Scholar
• Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020;395(10229):1054–1062.
   PubMed Web of Science ®Google Scholar
• Zheng KI, Feng G, Liu WY, et al. Extrapulmonary complications of COVID-19: a multisystem disease? J Med Virol. 2021;93(1):323–335.
   PubMed Web of Science ®Google Scholar
• Zakurdaeva K, Gavrilina OA, Vasileva AN, et al. COVID-19 and hematologic diseases: risk factors and long-term follow-up of CHRONOS19 Registry. JCO. 2021;39(15_suppl):e18715–e18715.
   Web of Science ®Google Scholar
• Rahman MA, Shanjana Y, Tushar MI, et al. Hematological abnormalities and comorbidities are associated with COVID-19 severity among hospitalized patients: Experience from Bangladesh. PLOS One. 2021;16(7):e0255379.
   PubMed Web of Science ®Google Scholar
• Piel FB, Steinberg MH, Rees DC. Sickle cell disease. Longo DL, editor. N Engl J Med. 2017;376(16):1561–1573.
   PubMed Web of Science ®Google Scholar
• Kato GJ, Piel FB, Reid CD, et al. Sickle cell disease. Nat Rev Dis Prim. 2018;4:1–22.
   PubMed Web of Science ®Google Scholar
• Salinas Cisneros G, Thein SL. Recent advances in the treatment of sickle cell disease. Front Physiol. 2020;11:435.
   PubMed Web of Science ®Google Scholar
• Jang T, Poplawska M, Cimpeanu E, et al. Vaso-occlusive crisis in sickle cell disease: a vicious cycle of secondary events. J Transl Med. 2021;19(1):1–11.
   PubMed Web of Science ®Google Scholar
• Friend A, Girzadas D. Acute Chest Syndrome. StatPearls. 2021.
   Google Scholar
• Van Tuijn CFJ, Nur E, Van Beers EJ, et al. Acute chest syndrome in sickle cell disease due to the new influenza A (H1N1) virus infection. Am J Hematol. 2010;85(4):303–304.
   PubMed Web of Science ®Google Scholar
• Strouse JJ, Reller ME, Bundy DG, et al. Severe pandemic H1N1 and seasonal influenza in children and young adults with sickle cell disease. Blood. 2010;116(18):3431–3434.
   PubMed Web of Science ®Google Scholar
• Hoogenboom WS, Alamuri TT, McMahon DM, et al. Clinical outcomes of COVID-19 in patients with sickle cell disease and sickle cell trait: A critical appraisal of the literature. Blood Rev. 2022;53:100911.
   Web of Science ®Google Scholar
• Sayad B, Karimi M, Rahimi Z. Sickle cell disease and COVID‐19: Susceptibility and severity. Pediatr Blood Cancer. 2021;68(8):e29075.
   PubMedGoogle Scholar
• The Cochrane Collaboration. Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 [Internet]. Higgins JPT, Green S, editors. Cochrane; 2011 [cited 2021 Jun 19]. Available from: https://training.cochrane.org/handbook.
   Google Scholar
• Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA Statement for Reporting Systematic Reviews and Meta-Analyses of Studies That Evaluate Health Care Interventions: Explanation and Elaboration. PLoS Med. 2009;6(7):e1000100.
   PubMed Web of Science ®Google Scholar
• Eriksen MB, Frandsen TF. The impact of patient, intervention, comparison, outcome (PICO) as a search strategy tool on literature search quality: a systematic review. J Med Libr Assoc. 2018;106(4):420–431.
   PubMed Web of Science ®Google Scholar
• Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159–174.
   PubMed Web of Science ®Google Scholar
• GA Wells BSDOJPVWMLPT. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. 2009.
   Google Scholar
• Sterne JAC, Egger M, Smith GD. Investigating and dealing with publication and other biases in meta-analysis. BMJ. 2001;323(7304):101–105.
   PubMed Web of Science ®Google Scholar
• Lima WG, Brito JCM, Cardoso BG, et al. Rate of polymyxin resistance among Acinetobacter baumannii recovered from hospitalized patients: a systematic review and meta-analysis. Eur J Clin Microbiol Infect Dis. 2020;39(8):1427–1438.
   PubMed Web of Science ®Google Scholar
• Singh A, Brandow AM, Panepinto JA. COVID-19 in individuals with sickle cell disease/trait compared with other Black individuals. Blood Adv. 2021;5(7):1915–1921.
   PubMed Web of Science ®Google Scholar
• Mucalo L, Brandow AM, Dasgupta M, et al. Comorbidities are risk factors for hospitalization and serious COVID-19 illness in children and adults with sickle cell disease. Blood Adv. 2021;5(13):2717–2724.
   PubMed Web of Science ®Google Scholar
• Arlet J, Lionnet F, Khimoud D, et al. Risk factors for severe COVID-19 in hospitalized sickle cell disease patients: a study of 319 patients in France. Am J Hematol. 2022;97(3):E86–E91.
   Web of Science ®Google Scholar
• Matkar S, Gangawane A. Laboratory investigation and clinical outcomes in sickle cell disease patients infected with COVID-19: a single-center experience in India. Med Sci. 2021;25:1522–1529.
   Web of Science ®Google Scholar
• Clift AK, Saatci D, Coupland CAC, et al. Sickle cell disorders and severe COVID-19 outcomes: a cohort study. Ann Intern Med. 2021;174(10):1483–1487.
   PubMed Web of Science ®Google Scholar
• Hoogenboom WS, Fleysher R, Soby S, et al. Individuals with sickle cell disease and sickle cell trait demonstrate no increase in mortality or critical illness from COVID-19 - a fifteen hospital observational study in the Bronx, New York. Haematologica. 2021;106(11):3014–3016.
   PubMed Web of Science ®Google Scholar
• Singh A, Brandow AM, Panepinto J. COVID-19 Outcomes in Individuals with Sickle cell disease and sickle cell trait compared to Blacks without sickle cell disease or trait. Blood. 2020;136(Supplement 1):54–56.
   Google Scholar
• Wang CC, Prather KA, Sznitman J, et al. Airborne transmission of respiratory viruses. Science. 2021;373(6558):eabd9149.
   Google Scholar
• Elia GM, Angel A, Regacini R, et al. Acute chest syndrome and COVID-19 in sickle cell disease pediatric patients. Hematol Transfus Cell Ther. 2021;43(1):104–108.
   PubMedGoogle Scholar
• Minniti CP, Zaidi AU, Nouraie M, et al. Clinical predictors of poor outcomes in patients with sickle cell disease and COVID-19 infection. Blood Adv. 2021;5(1):207–215.
   PubMed Web of Science ®Google Scholar
• Telfer P, de la Fuente J, Sohal M, et al. Real-time national survey of COVID-19 in hemoglobinopathy and rare inherited anemia patients. Haematologica. 2020;105(11):2651–2654.
   PubMed Web of Science ®Google Scholar
• Bonanad C, García-Blas S, Tarazona-Santabalbina F, et al. The effect of Age on mortality in patients with COVID-19: a meta-analysis with 611,583 Subjects. J Am Med Dir Assoc. 2020;21(7):915–918.
   PubMed Web of Science ®Google Scholar
• Bialek S, Boundy E, Bowen V, et al. Severe outcomes among patients with Coronavirus Disease 2019 (COVID-19)—United States, February 12–March 16, 2020. MMWR Morb Mortal Wkly Rep. 2020;69(12):343–346.
   PubMed Web of Science ®Google Scholar
• Bowden A, Fox-Rushby JA. A systematic and critical review of the process of translation and adaptation of generic health-related quality of life measures in Africa, Asia, Eastern Europe, the Middle East, South America. Soc Sci Med. 2003;57(7):1289–1306.
   PubMed Web of Science ®Google Scholar
• World Health Organization, Regional Office for Europe. Review of social determinants and the health divide in the WHO European Region: final report. 2004.
   Google Scholar
• Quispe-Laime AM, Bracco JD, Barberio PA, et al. H1N1 influenza A virus-associated acute lung injury: response to combination oseltamivir and prolonged corticosteroid treatment. Intensive Care Med. 2010;36(1):33–41.
   PubMed Web of Science ®Google Scholar
• Justino CC, Campanharo FF, Augusto MN, et al. COVID-19 as a trigger of acute chest syndrome in a pregnant woman with sickle cell anemia. Hematol Transfus Cell Ther. 2020;42(3):212–214.
   PubMedGoogle Scholar
• Dessap AM, Deux JF, Abidi N, et al. Pulmonary artery thrombosis during acute chest syndrome in sickle cell disease. Am J Respir Crit Care Med. 2011;184(9):1022–1029.
   PubMed Web of Science ®Google Scholar
• Poor HD. Pulmonary thrombosis and thromboembolism in COVID-19. Chest. 2021;160(4):1471–1480.
   PubMed Web of Science ®Google Scholar
• Kasinathan S, Ashraf HM, Minkowitz S, et al. COVID-19 infection and acute pulmonary embolism in an adolescent female with sickle cell disease. Cureus. 2020;12(12):e12348.
   PubMedGoogle Scholar
• De Souza Vilela T, Aparecida J, Braga P, et al. Hemoglobinopathy and pediatrics in the time of COVID-19. 2021.
   Google Scholar
• de Azevedo JTC, Malmegrim KCR. Immune mechanisms involved in sickle cell disease pathogenesis: current knowledge and perspectives. Immunol Lett. 2020;224:1–11.
   PubMed Web of Science ®Google Scholar
• Balanchivadze N, Kudirka AA, Askar S, et al. Impact of COVID-19 infection on 24 patients with sickle cell disease. One center urban experience, Detroit, MI, USA. Hemoglobin. 2020;44(4):284–289.
   PubMed Web of Science ®Google Scholar
• Dressler DD. Are COVID-19 outcomes affected by sickle cell disease? Ann Interne Med. 2021;Jul 20.
   Google Scholar
• Ochocinski D, Dalal M, Black LV, et al. Life-threatening infectious complications in sickle cell disease: a concise narrative review. Front Pediatr. 2020;8:38.
   PubMed Web of Science ®Google Scholar
• Suzane C, Fonseca V, Araújo-Melo CA, et al. Lung function in patients with sickle cell anemia. Rev Paul Pedriatria. 2011;29:85–90.
   Google Scholar
• De A, Manwani D, Rastogi D. Airway inflammation in sickle cell disease-A translational perspective. Pediatr Pulmonol. 2018;53(4):400–411.
   PubMed Web of Science ®Google Scholar
• Arlet J-B, de Luna G, Khimoud D, et al. Prognosis of patients with sickle cell disease and COVID-19: a French experience. Lancet Haematol. 2020;7(9):e632–e634.
   PubMed Web of Science ®Google Scholar
• Park A, Iwasaki A. Type I and Type III interferons - induction, signaling, evasion, and application to combat COVID-19. Cell Host Microbe. 2020;27(6):870–878.
   PubMed Web of Science ®Google Scholar
• Lee AJ, Ashkar AA. The dual nature of type I and type II interferons. Front Immunol. 2018;9:2061.
   PubMed Web of Science ®Google Scholar
• McNab F, Mayer-Barber K, Sher A, et al. Type I interferons in infectious disease. Nat Rev Immunol. 2015;15(2):87–103.
   PubMed Web of Science ®Google Scholar
• Hadjadj J, Yatim N, Barnabei L, et al. Impaired type I interferon activity and inflammatory responses in severe COVID-19 patients. Science. 2020;369(6504):718–724.
   PubMed Web of Science ®Google Scholar